Acute Kidney Injury by Cisplatin and Renoprotective Strategies

Information

  • Research Project
  • 9324777
  • ApplicationId
    9324777
  • Core Project Number
    R01DK087843
  • Full Project Number
    3R01DK087843-06A1S1
  • Serial Number
    087843
  • FOA Number
    PA-13-302
  • Sub Project Id
  • Project Start Date
    4/1/2010 - 14 years ago
  • Project End Date
    2/29/2020 - 4 years ago
  • Program Officer Name
    KIMMEL, PAUL
  • Budget Start Date
    3/15/2016 - 8 years ago
  • Budget End Date
    2/28/2017 - 7 years ago
  • Fiscal Year
    2016
  • Support Year
    06
  • Suffix
    A1S1
  • Award Notice Date
    9/9/2016 - 7 years ago

Acute Kidney Injury by Cisplatin and Renoprotective Strategies

? DESCRIPTION (provided by applicant): Cisplatin is one of the most widely used and most potent cancer therapy drugs. However, the use of cisplatin is associated with a major side-effect of nephrotoxicity, resulting in acute kidney injury (cisplatin-AKI) in over 25% of patients. The mechanism of cisplatin-AKI remains unclear and effective renoprotective approaches are not available. We have recently unveiled a critical role of PKC? in cisplatin-AKI and, remarkably, inhibition of PKC? not only protects kidneys but can also enhance the chemotherapy effect of cisplatin in tumors. Despite these findings, it is largely unclear how PKC? inhibition can protect kidneys, while killing cancer cells. We have demonstrated autophagy induction in cisplatin-AKI and its critical role of kidney protection. Moreover, mitophagy that removes damaged mitochondria via autophagy has been suggested. Mechanistically, our preliminary work supports the involvement of p53 and PKC? in autophagy regulation during cisplatin-AKI. We hypothesize that: 1) mitophagy is activated during cisplatin-AKI and accounts largely for the renoprotective effect of autophagy; 2) p53 contributes to autophagy induction in cisplatin-AKI, whereas PKC? plays an autophagy suppressive role; and 3) inhibition of PKC? may protect kidneys during cisplatin chemotherapy by enhancing autophagy. To test this hypothesis, we propose to: 1) elucidate mitophagy as a protective mechanism of autophagy in cisplatin-AKI; 2) determine the autophagy-promoting role of p53 in cisplatin-AKI; 3) delineate the autophagy-suppressing role of PKC? in cisplatin-AKI; and 4) test the hypothesis that PKC? inhibition protects kidneys through enhancing autophagy by analyzing the effects of PKC? inhibition in autophagy-suppressed and non-suppressed mice. Completion of the research will not only gain significant insights into autophagy protection and regulation in renal pathogenesis, but will also elucidate autophagy as a mechanism of the renoprotective effect of PKC? inhibition, suggesting a novel therapeutic strategy for kidney protection during chemotherapy in cancer patients.

IC Name
NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
  • Activity
    R01
  • Administering IC
    DK
  • Application Type
    3
  • Direct Cost Amount
    36931
  • Indirect Cost Amount
    13465
  • Total Cost
    50396
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    847
  • Ed Inst. Type
    SCHOOLS OF MEDICINE
  • Funding ICs
    NIDDK:50396\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    GEORGIA REGENTS UNIVERSITY
  • Organization Department
    BIOLOGY
  • Organization DUNS
    809593387; 966668691
  • Organization City
    AUGUSTA
  • Organization State
    GA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    309120004
  • Organization District
    UNITED STATES